Evidence map›Paper›PMID 35574036›Full record

ArticleFrontiers in endocrinology2022

Taxonomic and Functional Fecal Microbiota Signatures Associated With Insulin Resistance in Non-Diabetic Subjects With Overweight/Obesity Within the Frame of the PREDIMED-Plus Study.

Alessandro Atzeni, Thomaz F S Bastiaanssen, John F Cryan, Francisco J Tinahones, Jesús Vioque, Dolores Corella, Montserrat Fitó, Josep Vidal, Isabel Moreno-Indias, Ana M Gómez-Pérez and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. [Relationship Between Different Traditional Chinese Medicine Syndrome Types and Gut Microbiota in Patients With Type 2 Diabetes Mellitus].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 2 countries.

Alessandro AtzeniDepartment of Biochemistry and Biotechnology, Universitat Rovira i Virgili, Reus, Spain.
Thomaz F S BastiaanssenAPC Microbiome Ireland, Department of Anatomy and Neuroscience, University College Cork, Cork, Ireland.
John F CryanAPC Microbiome Ireland, Department of Anatomy and Neuroscience, University College Cork, Cork, Ireland.
Francisco J TinahonesCentro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
Jesús VioqueInstituto de Investigación Sanitaria y Biomédica de Alicante, ISABIAL-Universidad Miguel Hernández (UMH), Alicante, Spain.
Dolores CorellaCentro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
Montserrat FitóCentro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
Josep VidalEndocrinology and Nutrition Department, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clinic Universitari, Barcelona, Spain.
Isabel Moreno-IndiasCentro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
Ana M Gómez-PérezCentro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
Laura Torres-ColladoInstituto de Investigación Sanitaria y Biomédica de Alicante, ISABIAL-Universidad Miguel Hernández (UMH), Alicante, Spain.
Oscar ColtellCentro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
Olga CastañerCentro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
Monica BullóDepartment of Biochemistry and Biotechnology, Universitat Rovira i Virgili, Reus, Spain.
Jordi Salas-SalvadóDepartment of Biochemistry and Biotechnology, Universitat Rovira i Virgili, Reus, Spain.
Centro de Investigación Biomédica en Red · ESInstituto de Salud Carlos III · ESInstituto de investigación sanitaria y biomédica de AlicanteUniversidad Rovira i Virgili · ESAPC Microbiome Institute · IEConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESInstituto de Investigación Biomédica de Málaga · ESUniversitat Jaume I · ESUniversity College Cork · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: An altered gut microbiota has been associated with insulin resistance, a metabolic dysfunction consisting of cellular insulin signaling impairment. The aim of the present study is to determine the taxonomic and functional fecal microbiota signatures associated with HOMA-IR index in a population with high cardiovascular risk. Methods: A total of 279 non-diabetic individuals (55-75 years aged) with overweight/obesity and metabolic syndrome were stratified according to tertiles of HOMA-IR index. Blood biochemical parameters, anthropometric measurements and fecal samples were collected at baseline. Fecal microbial DNA extraction, 16S amplicon sequencing and bioinformatics analysis were performed. Results: Conclusions: Specific taxonomic and functional fecal microbiota signatures associated with insulin resistance were identified in a non-diabetic population with overweight/obesity at high cardiovascular risk. These findings suggest that tailoring therapies based on specific fecal microbiota profiles could be a potential strategy to improve insulin sensitivity.

Indexed as

Insulin ResistanceMicrobiotaAgedFecesHumansObesityOverweight16S sequencingfecal microbiotagut metabolic modulesHOMA-IRinsulin resisitance

Identifiers

PMID35574036
PMCPMC9097279
OpenAlexW4285740494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.